---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-049754"
form_type: "8-K"
ticker: "CVKD"
cik: "0001937993"
company_name: "Cadrenal Therapeutics, Inc."
filed_at: "2026-04-30T23:59:59+00:00"
generated_at: "2026-05-15T01:09:56.923892+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# Cadrenal completes FDA End-of-Phase 2 meeting; gets guidance for Phase 3 pivotal trial of CAD-1005 in HIT

## Summary
- Phase 2 data showed >25% absolute reduction in thrombotic events when CAD-1005 added to standard anticoagulant therapy.
- Planned Phase 3 trial: randomized, blinded, placebo-controlled; ~120 patients at up to 50 sites worldwide.
- Primary endpoint: incidence of new or worsening thrombotic events (centrally adjudicated) in SRA-confirmed HIT patients.
- Projected NDA submission in 2029; first randomized, blinded, placebo-controlled registration trial in HIT.

## SEC filing metadata
- accession: 0001213900-26-049754
- form_type: 8-K
- ticker: CVKD
- cik: 0001937993
- company_name: Cadrenal Therapeutics, Inc.
- filed_at: 2026-04-30T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937993/000121390026049754/0001213900-26-049754-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937993/000121390026049754/ea0288376-8k_cadrenal.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-049754
- JSON: https://secwatch.observer/filing/0001213900-26-049754.json
- Plain text: https://secwatch.observer/filing/0001213900-26-049754.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.